These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 21441776)
1. Cost of pneumococcal infections and cost-effectiveness analysis of pneumococcal vaccination at risk adults and elderly in Turkey. Akin L; Kaya M; Altinel S; Durand L Hum Vaccin; 2011 Apr; 7(4):441-50. PubMed ID: 21441776 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in São Paulo State, Brazil. Neto JT; de Araujo GT; Gagliardi A; Pinho A; Durand L; Fonseca M Hum Vaccin; 2011 Oct; 7(10):1037-47. PubMed ID: 21941088 [TBL] [Abstract][Full Text] [Related]
3. [Cost effectiveness of vaccination against pneumococcal bacteremia in the elderly: the results in Belgium]. De Graeve D; Verhaegen J; Ament A; Baltussen R Acta Clin Belg; 2000; 55(5):257-65. PubMed ID: 11109640 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy. Boccalini S; Bechini A; Levi M; Tiscione E; Gasparini R; Bonanni P Hum Vaccin Immunother; 2013 Mar; 9(3):699-706. PubMed ID: 23295824 [TBL] [Abstract][Full Text] [Related]
5. Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65 years-and-above in Switzerland. Owusu-Edusei K; Favre-Bulle A; Tsoumani E; Mutschler T; Cossrow N Vaccine; 2024 May; 42(13):3239-3246. PubMed ID: 38609806 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. Sisk JE; Moskowitz AJ; Whang W; Lin JD; Fedson DS; McBean AM; Plouffe JF; Cetron MS; Butler JC JAMA; 1997 Oct 22-29; 278(16):1333-9. PubMed ID: 9343464 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia. Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163 [TBL] [Abstract][Full Text] [Related]
8. Assessing costs and cost effectiveness of pneumococcal disease and vaccination within Kaiser Permanente. Black S; Lieu TA; Ray GT; Capra A; Shinefield HR Vaccine; 2000 Dec; 19 Suppl 1():S83-6. PubMed ID: 11163469 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden. Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274 [TBL] [Abstract][Full Text] [Related]
10. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain. Asensi F; De Jose M; Lorente M; Moraga F; Ciuryla V; Arikian S; Casciano R; Vento M Value Health; 2004; 7(1):36-51. PubMed ID: 14720129 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland. Ess SM; Schaad UB; Gervaix A; Pinösch S; Szucs TD Vaccine; 2003 Jul; 21(23):3273-81. PubMed ID: 12804858 [TBL] [Abstract][Full Text] [Related]
13. Impact of routine PCV7 (Prevenar) vaccination of infants on the clinical and economic burden of pneumococcal disease in Malaysia. Aljunid S; Abuduxike G; Ahmed Z; Sulong S; Nur AM; Goh A BMC Infect Dis; 2011 Sep; 11():248. PubMed ID: 21936928 [TBL] [Abstract][Full Text] [Related]
14. Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for adults in Germany. Kuchenbecker U; Chase D; Reichert A; Schiffner-Rohe J; Atwood M PLoS One; 2018; 13(5):e0197905. PubMed ID: 29795647 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of pneumococcal conjugate vaccination in Georgia. Komakhidze T; Hoestlandt C; Dolakidze T; Shakhnazarova M; Chlikadze R; Kopaleishvili N; Goginashvili K; Kherkheulidze M; Clark AD; Blau J Vaccine; 2015 May; 33 Suppl 1():A219-26. PubMed ID: 25919165 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of the introduction of the pneumococcal polysaccharide vaccine in elderly Colombian population. Castañeda-Orjuela C; Alvis-Guzmán N; Paternina AJ; De la Hoz-Restrepo F Vaccine; 2011 Oct; 29(44):7644-50. PubMed ID: 21854825 [TBL] [Abstract][Full Text] [Related]
17. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting. Mangtani P; Roberts JA; Hall AJ; Cutts FT Int J Epidemiol; 2005 Jun; 34(3):565-74. PubMed ID: 15764694 [TBL] [Abstract][Full Text] [Related]
18. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China. Shen K; Wasserman M; Liu D; Yang YH; Yang J; Guzauskas GF; Wang BCM; Hilton B; Farkouh R PLoS One; 2018; 13(7):e0201245. PubMed ID: 30044865 [TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of standing order programs for pneumococcal vaccination of hospitalized elderly patients. Middleton DB; Lin CJ; Smith KJ; Zimmerman RK; Nowalk MP; Roberts MS; Fox DE Infect Control Hosp Epidemiol; 2008 May; 29(5):385-94. PubMed ID: 18521990 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]